Patent · US Active

Compositions and methods for treating peritoneal cancers

US10071118B2 · kind B2 · utility

2Cited by
0References
11Claims
0Family size

Assignee

Inventors

Key dates

Filing dateJul 14, 2016
Grant dateSep 11, 2018
Priority date—
Expiry dateJul 14, 2036

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC07K2319/33
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

The present disclosure provides compositions and methods for treating a peritoneal cancer in a subject. The methods include administering a T cell which is genetically modified to express a chimeric T cell receptor protein. The chimeric T cell receptor protein may include a T cell receptor signaling domain fused to the tumor associated antigen-binding fragment of an antibody or a T cell receptor signaling domain fused to a naturally occurring ligand which specifically binds to a tumor cell surface protein. The compositions and methods disclosed herein are therapeutically effective to reduce, for example, tumor burden, abdominal ascites, peritoneal mucin, or serum tumor marker levels.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.